Compare Fox Corp Class A (FOXA) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fox Corp Class A vs Vertex Pharmaceuticals Incorporated — how do they compare? Fox Corp Class A trades at $63.88 (market cap $25.36B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 5× Fox Corp Class A's market cap, and Fox Corp Class A pays a 0.91% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Fox Corp Class A for 34 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| FOXA | VRTX | |
|---|---|---|
Market Cap | $25.36B | $127.55B |
Volume | 2,566,954 | 1,487,944 |
Sector | Media | Health |
52-Week High | $76.11 | $557.96 |
52-Week Low | $48.79 | $407.37 |
Typical Hold Time | 34 Days | 120 Days |
Enterprise Value | $28.72B | $121.68B |
Dividend Yield | 0.91% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FOXA trades at $62.70, up 1.0% with a bearish technical signal despite strong fundamentals. The company reported robust earnings beats in recent quarters with Q2 2026 EPS of $1.79 beating expectations by 24%. Revenue grew to $16.3B in 2025 with net income margin expanding to 13.88%. The pending $22B Roku acquisition faces extended DOJ review, creating regulatory uncertainty while CEO Lachlan Murdoch recently purchased $10.3M in shares.
FOXA presents a compelling value case with attractive valuation multiples (P/E 16.33, P/S 1.61) and strong profitability (ROE 14.29%). Analyst consensus targets $72.00 with 52% buy ratings, offering 15% upside potential. Key risks include regulatory hurdles for the Roku deal and projected 2026 margin compression. The stock's current technical weakness may provide entry opportunity for fundamental investors.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% on the day, with a bearish technical signal despite a neutral oscillator reading. The company reported strong 2025 revenue of $12.00B and net income of $3.95B, with a net margin of 35%. Recent positive Phase 2b data for its kidney disease drug inaxaplin highlights pipeline expansion beyond cystic fibrosis dominance. Analyst consensus is strongly bullish with an 83.9% buy rating and a $573.50 price target, implying 13.4% upside.
The outlook for VRTX is positive, driven by its profitable core business and promising pipeline, but faces risks from clinical trial outcomes and competitive pressures. The stock's current valuation at a P/E of 29.45 is reasonable given its growth prospects, though investors should monitor execution on new drug approvals and market adoption.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Fox Corp Class A
Fox operates in cable networks and television. Its cable segment includes Fox News, Fox Business, and sports channels, while its TV segment covers the Fox network, 29 local stations (18 Fox-affiliated), and the ad-supported streaming service Tubi. After selling most of its entertainment assets to Disney in 2019, Fox now focuses on live news and sports, primarily within pay-TV. The Murdoch family controls the company.
Read more on FOXA →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
